Moinpour, Carol M., Darke, Amy K., Donaldson, Gary W., Thompson, Ian M., Langley, Connie, Ankerst, Donna Pauler, ...
Background The Prostate Cancer Prevention Trial (PCPT) was a randomized, double-blind, placebo-controlled study of the efficacy of finasteride in preventing prostate cancer in 18882 men aged 55 years...
Petrylak, Daniel P., Ankerst, Donna Pauler, Jiang, Caroline S., Tangen, Catherine M., Hussain, Maha H. A., Lara, Primo N., ...
Background: The identification of surrogate endpoints that can replace true outcome endpoints is crucial to the rapid evaluation of new cancer drugs. Retrospective analyses of phase II and III trials...
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2006)
Thompson, Ian M., Ankerst, Donna Pauler, Chi, Chen, Goodman, Phyllis J., Tangen, Catherine M., Lucia, M. Scott, ...
Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate...
Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer (2006)
Thompson, Ian M., Chi, Chen, Ankerst, Donna Pauler, Goodman, Phyllis J., Tangen, Catherine M., Lippman, Scott M., ...
Background: In the Prostate Cancer Prevention Trial (PCPT), men receiving finasteride had a 24.8% lower risk of prostate cancer than men receiving placebo but a higher risk of high-grade cancer. We...